Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Dianthus Therapeutics Inc | DNTH | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 26.96 | 04:09:51 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 26.96 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 6.58 - 33.77 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 26.96 | USD |
Dianthus Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 399.49M | 14.82M | - | 2.83M | -43.56M | -2.94 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Dianthus Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical DNTH Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 20.40 | 27.10 | 19.845 | 23.51 | 208,364 | 6.56 | 32.16% |
| 1 Month | 25.75 | 27.10 | 19.845 | 22.67 | 150,188 | 1.21 | 4.70% |
| 3 Months | 29.25 | 33.77 | 19.73 | 24.71 | 156,957 | -2.29 | -7.83% |
| 6 Months | 7.90 | 33.77 | 6.58 | 23.57 | 134,269 | 19.06 | 241.27% |
| 1 Year | 10.40 | 33.77 | 6.58 | 22.63 | 95,732 | 16.56 | 159.23% |
| 3 Years | 10.40 | 33.77 | 6.58 | 22.63 | 95,732 | 16.56 | 159.23% |
| 5 Years | 10.40 | 33.77 | 6.58 | 22.63 | 95,732 | 16.56 | 159.23% |
Dianthus Therapeutics Description
| Magenta Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing novel medicines to extend the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy. The pipeline of the company includes MGTA-117, MGTA-145, and others. |
